CD52 Molecule (CD52) ELISA Kits

Mouse (Murine) CD52 Molecule (CD52) interaction partners

1. Soluble CD52 is used by certain CD4-positive cells to suppress target celss via the inhibitory receptor Siglec-10.

2. expression is induced in the mouse uterus at the time of embryo implantation

3. Genetic background determines the requirement for B7 costimulation in autoimmunity induction. Backcrossed B7.1/B7.2 deficient (-/-)mice on C57BL/6 (B6) or SJL backgrounds had different susceptibility to induced experimental autoimmune encephalomyelitis.

4. study examined the tissue distribution, molecular composition and immunogenicity of mouse male reproductive tract-CD52

5. The results indicate CD52 is not required for fertilization in the mouse either in vivo or in vitro.

6. Study helps to precisely define CD52 expression in the tumor cell population of PTCL and might therefore be valuable when evaluating the response to alemtuzumab therapy in prospective clinical trials.

Human CD52 Molecule (CD52) interaction partners

1. soluble CD52 exerts a concerted immunosuppressive effect by first sequestering HMGB1 to nullify its proinflammatory Box B, followed by binding to the inhibitory Siglec-10 receptor, triggering recruitment of SHP1 to the intracellular immunoreceptor tyrosine-based inhibitory motif of Siglec-10 and its interaction with the TCR.

2. CD52 is a novel prognostic NSC marker and a potential NSC target in a subset of patients with MDS and AML, which may have clinical implications and may explain clinical effects produced by alemtuzumab in these patients.

3. A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease.

4. carbohydrate moiety of sperm protein interferes with the complement system via binding to C1q

5. CT60 single-nucleotide polymorphism of CTLA4 is a surrogate marker for donor lymphocyte infusion outcome after allogeneic cell transplantation for acute leukemia

6. Clonal large granular lymphocytes exhibited decreased CD52 expression post-therapy in patients refractory to treatment.

7. Our bioinformatics findings suggest that CD52 polymorphism may affect the efficiency of GPI anchor formation and thus may indirectly alter the response to anti-CD52 agents like alemtuzumabin renal transplantation.

8. Review article on CD52 structure and function.

9. HE5(CD52) mRNA and protein, expressed in epithelial cells of the distal epididymis, were not affected by the obstruction of the vas deferens.

10. The relationship between this differential insertion and differences in glycosylation of rat and human CD52 is discussed.

11. CD52 is widely expressed on human mast cells (MCs) and Waldenstrom's Macroglobulinemia bone marrow lymphoplasmacytic cells and provide the preclinical rationale for the use of alemtuzumab in the treatment of WM and possibly other MC-related disorders.

12. In this study, we identified the antigen of 4C8 mAb as CD52. CD52 is a costimulatory molecule for induction of CD4-positive T cells.

13. In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy.

14. Our data demonstrate differences in the intensity of the CD52 antigen expression between B-lymphocytes and tumor lymphocytes of B-CLL patients, and between B-CLL and SLL tumor cells. CD52 antigen is expressed at low level on CD34(+) cells.

15. The semenogelin-CD52 soluble form is a direct consequence of the liquefaction process in human semen.

16. We first showed the expression of CD52 in human cumulus cells. CD52 has some functional roles around fertilization in females as well as in males.

17. A review on CD52 expression and function